GLP-1 for Alcohol Addiction and Smoking: What the Research Really Shows

Some people taking semaglutide say that the glass of wine they once looked forward to suddenly sits unfinished. Others report that cigarettes feel less compelling. These experiences have prompted a serious scientific question: could GLP-1 medicines eventually help to treat alcohol or nicotine addiction?

The short answer: GLP-1 receptor agonists are promising experimental treatments for addiction, but they are not currently established or licensed UK treatments for alcohol dependence or smoking cessation. Early human studies suggest semaglutide may reduce alcohol craving and certain measures of drinking. Evidence for smoking is less developed: craving may fall, but we do not yet know whether these medicines reliably help people quit long term.

That distinction matters. A person in Cardiff who notices less interest in lager after starting Wegovy for weight management is describing a potentially meaningful effect. It is not, however, proof that a weekly injection can safely replace an alcohol assessment, medically supported withdrawal or psychological treatment. The same applies to someone in Manchester who finds cigarettes less satisfying after starting a GLP-1 medicine for diabetes.

What are GLP-1 receptor agonists?

GLP-1 stands for glucagon-like peptide-1, a hormone released by the gut after eating. It helps regulate blood glucose, slows the rate at which food leaves the stomach and sends signals involved in fullness. GLP-1 receptor agonists imitate some of these effects.

Semaglutide is the ingredient in Ozempic, Wegovy and Rybelsus, although the products have different licensed uses, doses and formulations. Ozempic is associated with type 2 diabetes; Wegovy is licensed for weight management in eligible patients. Liraglutide and dulaglutide belong to the same broad medicine class. Tirzepatide, sold as Mounjaro, acts on both GIP and GLP-1 receptors and is not technically a GLP-1-only medicine.

None should be treated as interchangeable, borrowed from another person or bought from an unverified online seller. In Britain, these are prescription medicines intended for specific medical indications—not general-purpose “craving injections”.

Why might a gut hormone affect addiction?

Addiction is not simply a failure of willpower. Alcohol and nicotine can train the brain to attach unusually strong importance to a substance, the situations surrounding it and the relief or reward expected from it. A pub sign, the end of a hospital shift or the first coffee of the morning may become a cue before a person has consciously decided what to do.

GLP-1 receptors are found not only in the digestive system but also in brain regions connected with appetite, motivation and reward. Animal research suggests that stimulating these receptors can reduce alcohol and nicotine seeking. Scientists are investigating several overlapping possibilities:

the substance may feel less rewarding or less urgent;
cue-triggered wanting may become quieter;
greater satiety may extend beyond food to other rewarding behaviours;
nausea or altered taste may temporarily make alcohol or cigarettes less appealing; and
improvements in blood glucose, weight or general wellbeing may indirectly change habits.

The nausea explanation is unlikely to tell the whole story, but it is an important source of confusion. If a person drinks less only because they feel unwell during dose escalation, that is different from a medicine changing the underlying biology of craving. Good trials must separate those effects.

GLP-1 for alcohol addiction: what does the research show?

The strongest early human evidence came from a 2025 phase 2 randomised trial of once-weekly semaglutide. Forty-eight adults with alcohol use disorder received low-dose semaglutide or placebo for nine weeks. They were not actively seeking alcohol treatment, and most were overweight or living with obesity. This was therefore a small, specialised sample—not a cross-section of everyone receiving care for alcohol dependence in Birmingham, Glasgow or elsewhere in the UK.

Compared with placebo, semaglutide reduced the amount consumed during a controlled laboratory drinking task. Across the treatment period, it also reduced drinks per drinking day, weekly alcohol craving and heavy-drinking days. However, it did not significantly change every outcome: average drinks per calendar day and the number of drinking days did not differ significantly.

That mixed result is precisely why the study is encouraging but not conclusive. It suggests a real biological signal, yet it does not demonstrate that semaglutide produces sustained abstinence, prevents relapse over years, reduces alcohol-related deaths or works better than established treatment.

A large Swedish registry study also found fewer alcohol-related hospital admissions during periods when people with diagnosed alcohol use disorder were using certain GLP-1 medicines, especially semaglutide. This supports further investigation, but an observational association cannot prove that the medicine caused the reduction. People prescribed GLP-1 drugs may differ in healthcare contact, metabolic health, motivation and many other ways that affect the result.

What people mean by “alcohol noise”

Online discussions sometimes use the phrase “alcohol noise” for the repetitive mental negotiation around drinking: whether to buy a bottle, when to open it, how much remains and whether another drink is available. Some GLP-1 users describe that internal chatter fading in the same way that “food noise” can become quieter.

These accounts deserve to be studied; many research questions begin with an unexpected clinical observation. But anecdotes are particularly vulnerable to expectation, publicity and selective reporting. People who experience a striking change tend to post about it. People who notice nothing may say nothing at all.

Ozempic for smoking cessation: where is the evidence?

The nicotine story is earlier and less certain. A small pilot trial published in 2021 tested weekly exenatide alongside nicotine patches and counselling in people with prediabetes or overweight. The combination showed better short-term abstinence and reduced craving and post-cessation weight gain. Because exenatide was added to established stop-smoking care, the trial could not show that a GLP-1 medicine alone was responsible for every benefit.

In 2026, researchers reported a phase 2a randomised trial of semaglutide in 24 adults who smoked daily but were not trying to quit. Semaglutide reduced weekly cigarette craving and body weight. Yet the study’s main laboratory comparisons were not significant, and the medicine did not significantly reduce the number of cigarettes smoked per day. The sample was also smaller than planned, making firm conclusions impossible.

This is not evidence that “Ozempic stops smoking”. At best, it suggests that GLP-1 signalling may influence nicotine craving and deserves larger cessation trials in people who genuinely intend to quit. Future studies need to measure biochemically confirmed abstinence at six or twelve months, relapse, side effects and whether benefits remain after the injection stops.

Question	What the evidence currently suggests
Can semaglutide reduce alcohol craving?	Possibly. A small randomised trial found a significant reduction in weekly craving.
Does it reduce alcohol consumption?	Some measures improved, including drinks per drinking day and laboratory consumption, but not all drinking outcomes changed.
Can Ozempic help someone stop smoking?	Not established. Early studies show possible effects on craving, but convincing long-term quit data are lacking.
Is any GLP-1 medicine licensed in the UK for addiction?	No. Use specifically for alcohol or nicotine addiction remains experimental and off-label.
Should established treatment be replaced?	No. Current evidence-based medicines, behavioural support and specialist care remain the appropriate options.

Why the results should not be overhyped

There is a familiar pattern in medicine: a plausible mechanism, striking personal stories and encouraging early results can create certainty long before the evidence justifies it. Several questions remain unanswered.

The trials are small and short. Addiction frequently involves relapse, so a nine-week improvement is not the same as recovery maintained for a year.
Participants may not represent everyone. Much of the early research involved people who were overweight or had metabolic risk factors.
Craving is not the same as abstinence. A lower questionnaire score is useful, but health outcomes and sustained behaviour change matter more.
Blinding may be imperfect. Recognisable gastrointestinal effects can make participants suspect that they received the active drug.
The right dose is unknown. A dose suitable for obesity cannot simply be assumed to be the best dose for addiction.
We do not know what happens after treatment ends. Cravings may return, just as appetite and weight can change after GLP-1 treatment is stopped.

Are GLP-1 medicines safe to mix with alcohol?

There is no simple answer that applies to every product and patient. Semaglutide commonly causes nausea, vomiting, diarrhoea, constipation and tiredness. Alcohol can worsen nausea, affect blood glucose, add calories and impair judgement. Vomiting and diarrhoea can cause dehydration, which is more concerning if somebody is also drinking heavily or has kidney problems.

People with diabetes must consider the rest of their medication, because alcohol can contribute to low blood glucose—particularly when insulin or a sulfonylurea is involved. Severe, persistent abdominal pain, especially with vomiting, requires urgent medical advice because pancreatitis is one possible cause. A prescriber should also know about pregnancy plans, previous pancreatitis, gallbladder disease, severe digestive problems and all other medicines being taken.

Do not suddenly stop alcohol if you may be physically dependent. Morning shakes, sweating, retching, anxiety relieved by a drink, hallucinations or previous withdrawal seizures are warning signs. Abrupt withdrawal can cause seizures, delirium and death. Contact a GP or local alcohol service before cutting down. Call 999 or attend A&E for a seizure, severe confusion, hallucinations or severe withdrawal symptoms.

What help is available in the UK now?

A person does not need to wait for GLP-1 addiction research to mature before asking for effective help. The route may look slightly different in England, Wales, Scotland and Northern Ireland, but a GP, community pharmacist or local addiction service can help identify the right starting point.

For alcohol problems

Treatment can include a structured assessment, a medically supported detoxification when needed, psychological interventions and relapse-prevention medication. NICE recommends considering acamprosate or oral naltrexone with psychological treatment after successful withdrawal for suitable people; disulfiram may be considered in particular circumstances. These medicines have contraindications and monitoring requirements, so they must be selected with a clinician.

In Wales, DAN 24/7 offers confidential drug and alcohol advice; in other parts of the UK, the NHS website or a GP can direct someone to their local service. Whether a person lives near a large teaching hospital in London or in a rural part of Cumbria, asking for help early is worthwhile. Dependence is a medical problem, not a moral verdict.

For nicotine dependence

Current options are much better supported than semaglutide. They include nicotine replacement therapy—often a patch combined with a faster-acting product such as gum, lozenges or spray—and prescription medicines such as varenicline, cytisine or bupropion when appropriate. Behavioural support from a stop-smoking adviser improves the chance of success.

Local provision varies. Sessions may take place in a GP surgery, pharmacy, high-street clinic or by phone. Someone in Bristol who has relapsed after three quit attempts has not “failed three times”; they have learned where the difficult moments are, and a stop-smoking adviser can build the next attempt around that information.

Should you ask your doctor for semaglutide to curb cravings?

You can certainly tell your clinician about alcohol or nicotine cravings, including any change noticed after starting a prescribed GLP-1 medicine. That information may affect your care and is useful for pharmacovigilance and future research.

What is not sensible is requesting Ozempic solely as a proven addiction cure, increasing a dose to suppress cravings, or continuing a medicine against medical advice because it seems to reduce drinking. A clinician may prescribe a medicine off-label in some circumstances, but that is an individual professional decision based on evidence, risks, alternatives and the patient’s wider health—not something an online article can recommend.

If you already take a GLP-1 medicine: do not change the dose or stop it because of this article. Keep a simple record of cravings, alcohol units or cigarettes, side effects and mood, then discuss the pattern with your prescriber. Seek prompt help if substance use is becoming unsafe.

Frequently asked questions

Does Ozempic make you stop wanting alcohol?

Some people report less interest in alcohol, and early clinical evidence suggests semaglutide can reduce craving for some patients. Many people experience no such effect. It is not guaranteed and Ozempic is not licensed as an alcohol-dependence treatment.

Can Wegovy help with alcohol addiction?

Semaglutide—the active ingredient in Wegovy—has produced promising early trial results, but researchers have not yet established long-term effectiveness or safety as an alcohol-use-disorder treatment. Wegovy should only be used for the indication and dose prescribed.

Does semaglutide reduce nicotine cravings?

A very small 2026 randomised trial found reduced cigarette craving, but it did not significantly reduce cigarettes smoked per day. Larger trials involving people making a supported quit attempt are needed.

Will a GLP-1 medicine prevent weight gain after quitting smoking?

This is an appealing possibility and early exenatide research reported less post-cessation weight gain. It remains experimental. Fear of weight gain should not delay a quit attempt; a stop-smoking adviser can help plan for appetite, activity and treatment.

Can I buy semaglutide privately for addiction?

A legitimate prescriber must assess whether you meet an authorised medical indication and whether treatment is safe. Avoid sellers offering prescription injections without an appropriate consultation. Buying a weight-loss medicine does not turn it into an approved addiction treatment.

Could GLP-1 drugs treat other addictions?

Researchers are exploring other substance-use and compulsive behaviours, but evidence varies and is generally preliminary. A shared “reward” mechanism does not mean one medicine will work equally well for alcohol, nicotine, opioids, stimulants, gambling or binge eating.

The bottom line

GLP-1 agonists may become an important new chapter in addiction medicine. The alcohol findings are credible enough to justify larger trials, and the emerging nicotine data give researchers a reason to continue. But the story in 2026 is one of potential, not proof.

If future trials show sustained benefit, these medicines may be most useful as one part of care—reducing the volume of craving enough for counselling, relationships and new routines to gain a foothold. That would be valuable. It would not make recovery effortless, nor would it make existing treatments obsolete.

For now, nobody with alcohol dependence should risk an unsupervised sudden withdrawal, and nobody trying to stop smoking needs to wait for Ozempic. Evidence-based help is already available across the UK.

References and further help

This article is for general education and is not a diagnosis or individual medical advice. Research into GLP-1 medicines for addiction is developing rapidly; treatment decisions should be made with an appropriately qualified healthcare professional.